A blood screening test for Alzheimer's disease

Sid E. O'Bryant, Melissa Edwards, Leigh Johnson, James Hall, Alcibiades E. Villarreal, Gabrielle B. Britton, Mary Quiceno, C. Munro Cullum, Neill R. Graff-Radford

Research output: Contribution to journalArticlepeer-review

61 Scopus citations


Introduction: This study combined data across four independent cohorts to examine the positive and negative predictive values of an Alzheimer's disease (AD) blood test if implemented in primary care. Methods: Blood samples from 1329 subjects from multiple independent, multiethnic, community-based, and clinic-based cohorts were analyzed. A "locked-down" referent group of 1128 samples was generated with 201 samples randomly selected for validation purposes. Random forest analyses were used to create the AD blood screen. Positive (PPV) and negative (NPV) predictive values were calculated. Results: In detecting AD, PPV was 0.81, and NPV was 0.95 while using the full AD blood test. When detecting mild cognitive impairment, PPV and NPV were 0.74 and 0.93, respectively. Preliminary analyses were conducted to detect any "neurodegenerative disease". The full 21-protein AD blood test yielded a PPV of 0.85 and NPV of 0.94. Discussion: The present study creates the first-ever multiethnic referent sample that spans community-based and clinic-based populations for implementation of an AD blood screen.

Original languageEnglish (US)
Pages (from-to)83-90
Number of pages8
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
StatePublished - 2016


  • Alzheimer's disease
  • Blood test
  • Diagnosis
  • Predictive power
  • Primary care
  • Screening

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'A blood screening test for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this